Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science



Rating:

Share or cite this content

Citations should be made in the following way:
L. McGarvey (Belfast, United Kingdom), A. Morice (Hull, United Kingdom), J. Smith (Manchester, United Kingdom), M. Sher (Largo FL, United States of America), M. Vaezi (Nashville TN, United States of America), L. Guilleminault (Toulouse, France), A. Niimi (Nagoya, Japan), K. Roth (Berlin, Germany), R. Saarinen (Espoo, Finland), P. Vieira Pires (Wuppertal, Germany), M. Wosnitza (Wuppertal, Germany), P. Dicpinigaitis (Bronx NY, United States of America). Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study. 562

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19 Year: 2021 Late Breaking Abstract - Phase 2a randomised, double-blind, placebo-controlled, crossover study of a novel P2X3 receptor antagonist S-600918 in patients with refractory chronic cough Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019 Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trial Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia – The BESTCILIA randomized placebo-controlled trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Intensive care and infection Year: 2019 Late Breaking Abstract - The impact of regular bisoprolol on recovery with salbutamol in asthma; a double-blind randomised controlled trial Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Chinese herbs in treatment of postinfectious cough: A multi-centre, randomized, double-blind, placebo-controlled trial Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Effect of borago extract on moderate persistent asthma, a phase two randomized, double blind placebo-controlled clinical trial Source: International Congress 2016 – Asthma management Year: 2016 Late Breaking Abstract: High-dose vitamin D3 during intensive phase treatment of pulmonary tuberculosis: A double-blind randomised controlled trial Source: Annual Congress 2010 - Clinical tuberculosis Year: 2010 Efficacy of the Plasma Cluster® device in mild to moderate asthmatic children: A randomized, double-blind, placebo-controlled, proof-of-concept trial Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013 RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Efficacy and safety of a novel nicotine mouth spray in smoking cessation: A randomized, placebo-controlled, double blind, multicenter study with 52-week follow up Source: Annual Congress 2011 - Smoking cessation science Year: 2011 A double-blind, randomized, sham-controlled study of Targeted Lung Denervation in patients with moderate to severe COPD : AIRFLOW-2 One Year Outcomes Source: International Congress 2019 – Interventional pulmonology: a mixture of spices Year: 2019 Effects of ghrelin on the dyspnea pattern in cachectic COPD: Exploratory analysis of a substudy of a multicenter, randomized, double-blind, placebo-controlled trial of ghrelin treatment Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation Year: 2013 Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Late Breaking Abstract - CPAP treatment in the very elderly with Ostructive Sleep Apnea. Pooled results from two multicenter randomized controlled trials Source: Virtual Congress 2021 – Sleep across the lifespan in the new era of COVID - 19 Year: 2021